The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Small molecule inhibitors for CLL: which to use, sequencing, switching and combinations
There are now three small molecule inhibitors to choose from for the treatment of chronic lymphocytic leukemia (CLL): Ibrutinib, idelalisib and venetoclax. In this video, Susan O’Brien, MD, of the University of California, Irvine, CA, discusses the indications and reasoning for which to use, switching between them and sequencing. Prof. O’Brien also covers combining these agents with one other and antibodies, in addition to resistance. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
